RecruitingNot ApplicableNCT07421427

Adding Amantadine or Duloxetine to Pregabalin on Occurrence of Post Mastectomy Pain Syndrome

The Effect of Adding Amantadine or Duloxetine to Pregabalin on Occurrence of Post Mastectomy Pain Syndrome; Randomized Controlled Study


Sponsor

Cairo University

Enrollment

150 participants

Start Date

Feb 21, 2026

Study Type

INTERVENTIONAL

Conditions

Summary

This study aims to evaluate the additive effect of Amantadine or Duloxetine to Pregabalin on development of post mastectomy pain syndrome


Eligibility

Sex: FEMALEMin Age: 18 YearsMax Age: 65 Years

Inclusion Criteria4

  • Age from 18 to 65 years.
  • American society of anesthesiologists (ASA) Physical status II, III.
  • Body mass index (BMI): (20-40) kg/m2.
  • Type of surgery: patients undergoing modified radical mastectomy for breast cancer.

Exclusion Criteria7

  • Patient refusal.
  • Patients with Known sensitivity or contraindication to drug used in the study.
  • History of psychological disorders and/or chronic pain and drug abuse patients.
  • Previous administration of antidepressants, anticonvulsants, or opioids before surgery.
  • Severe respiratory or cardiac disorders.
  • Advanced liver or kidney disease.
  • Previous breast surgery

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGPregabalin

Two hours preoperative patient will receive one capsule of Pregabalin 75 mg (Lyrica 75 mg, Viatris) and) and one placebo tablet and will continue on both of them twice daily for seven days postoperative

DRUGPregabalin + Amantadine

Two hours preoperative patient will receive one capsule of pregabalin 75 mg (Lyrica 75 mg, Viatris) and one tablet of Amantadine 100 mg (PK-Merz 100 mg, MERZ Pharma) and will continue on both twice daily for seven days postoperative.

DRUGPregabalin + Duloxetine

Two hours preoperative patient will receive one capsule of pregabalin 75 mg (Lyrica 75 mg, Viatris) and one capsule of Duloxetine 30 mg (Cymbatex 30 mg, EVA Pharma) and will continue on both twice daily for seven days postoperative.


Locations(1)

Cairo University

Cairo, Egypt

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07421427


Related Trials